Vaccinomics: Scientists Are Devising Your Personal Vaccine

A new breed of vaccine is being developed that will make possible immunizations tailored to your genetic profile. But how long will it be until your personalized booster shots are ready?















Share on Tumblr

the human genome might some day empower the creation of personalized vaccines

ONE-OFF SHOT: Although truly personalized vaccine regimes might seem a far-off dream, some researchers are looking to genomics to usher in an era of vaccinomics. Image: ISTOCKPHOTO/FOTOGRAFIABASICA

Our bodies defeat infections in part because our immune system's genes are many and diverse. This genetic heterogeneity, however, has a downside: it means that we each respond differently to vaccines. For example, compared with women men routinely produce fewer pathogen-fighting antibodies after vaccination, and in the last large U.S. measles outbreak in 1989 10 percent of previously vaccinated children were not protected. But these limitations could one day be overcome thanks to a push to replace one-size-fits-all vaccines with genetically "personalized" immunizations that are safe and effective for everyone.

The idea of tailored vaccines is hardly new. Gregory Poland, the head of the Mayo Clinic's Vaccine Research Group, has been working to unite the fields of genomics and vaccinology—what he calls "vaccinomics"—for 22 years, in part because he has never been fully pleased with the existing vaccine paradigm. "It is a population-based or public health–based approach and, within limits, it has served us well," he says. "But it is has also engendered an antivaccine movement, because there are people who have side effects."

The past decade has seen vaccinomics inch much closer to reality. With the completion of the first phase of the Human Genome Project in 2000, and the advent of sequencing technologies that can detect gene variations such as single nucleotide polymorphisms (SNPs), for the first time scientists have the tools in hand to find the key immune genes and genetic networks that play roles in vaccine response.

Poland envisions a future in which people can opt to have their genome sequences stored on chips in their health insurance cards. At the doctor's office, computers would scan the chips to determine whether the person's gene sequences have been linked to vaccine side effects or weak responses. Then the patient and physician "will pick and choose an individualized program that best fits his or her genetics," Poland explains.

To be sure, this scenario is likely decades away. But information gleaned from genomics could soon improve vaccines in subtle but effective ways. In a 2007 paper published in The Journal of Allergy and Clinical Immunology Poland and his colleagues reported that people who have mutations in a gene for a protein called SLAM produce 70 percent fewer antibodies after live measles inoculation than people without the mutation. Normal SLAM binds to a measles protein present in the vaccine, helping the body launch an immune response. Poland suspects that the mutation changes SLAM's shape so that it cannot bind the protein. If scientists could design a vaccine that did not depend on SLAM, Poland wrote, it would protect more of the population.

Genes could also predict who will suffer from adverse reactions. In a March 2009 study published in Genes and Immunity, researchers at the National Center for Computational Toxicology compared the genetic signatures of 16 people who experienced smallpox vaccine side effects, including fever, rashes and enlarged lymph nodes, to 45 people who did not. Using these data, the team built a diagnostic model that predicts who is likely to experience these problems based on sequence differences in a gene coding for an immune protein called interleukin-4 as well as variations in serum concentrations of three other immune proteins. If people were warned that they might experience adverse reactions to a particular vaccine, they could instead opt to receive other preventative treatments, such as antiviral medications.

One of the biggest challenges for vaccinomics is that it is extremely difficult to identify the genes responsible for vaccine responses. Humans have thousands of immune system genes, and they interact with one another in complex ways; some, for instance, control others. "You're trying to understand the simultaneous contribution of hundreds to thousands of things happening at the same time," Poland says.

In addition, genetics is just part of the immune-response story. Poland and his colleagues have shown that genes are only responsible for 38.8 percent of the variation in the way people respond to the mumps vaccine virus and 45.7 percent of the disparity in how they respond to the rubella vaccine virus. What causes the rest is a mystery—environmental influences, perhaps, or differences in the amounts of protein being made from particular immune genes.

And even if scientists do put together all the pieces and find ways to develop genetically tailored vaccines, they will still have to "get these innovations out of the university setting, into the marketplace, and into the health care system," says Yann Joly, a lawyer and assistant professor in the Department of Human Genetics at McGill University in Montreal. Personalized vaccines might not be all that attractive to pharmaceutical companies, because introducing the genomic component will make manufacturing "even more complicated and less profitable," he says. "You also add a degree of uncertainty into it, because this is all new."

It is also possible that patients who are already wary of vaccines may be even more concerned about personalized inoculations, which have no public health track record as yet. "One hundred years from now we'll be much better at making pure and safer vaccines," says Paul Offit, director of the Vaccine Education Center at The Children's Hospital of Philadelphia. "I'm sure it will [initially] be met with the same level of distrust as is met with current science."

Poland, though, is optimistic. "There has been this deep schism between people who believe in vaccines and people who don't, and what's interesting is that both groups are highly attracted to this work we're doing," he says. What drives vaccine fears, he notes, is the knowledge that vaccines don't work for everyone and that they can, on rare occasions, cause serious side effects, such as Guillain–Barré syndrome, which develops in one out of every million people who receive the seasonal influenza vaccine. But with vaccinomics, "we'll actually be able to predict whether you need a vaccine, how many doses you need, and whether you're likely to have a serious side effect," he says. "The power of this—for human health—is undeniable."



7 Comments

Add Comment
View
  1. 1. lamorpa 04:42 PM 6/24/10

    I'm hoping a vaccine is developed for that segment of the population that maintains the baseless, paranoid delusion that vaccines are unsafe and should be avoided. I've heard that the jennymccarthyisanidiot vaccine is in development.

    Reply | Report Abuse | Link to this
  2. 2. Jui 08:51 PM 6/24/10

    Well, future, here we come! I am definitely excited by this, but as they said, the mass use of this is definitely going to take another half century, so I'm not counting on it.

    Reply | Report Abuse | Link to this
  3. 3. hawkeye 12:21 AM 6/25/10

    Ah yes, human nature.......do you suppose this is yet another dastardly socialistic plot by the Obama administration to spread autism among red blooded americans?

    Reply | Report Abuse | Link to this
  4. 4. Iahmad in reply to lamorpa 02:19 AM 6/25/10

    lamorpa;
    It will be still better to have a vaccine for all war mongers, state and non-state sponsors of terror, aparthied and racist people and so on. World will be such a wonderful place to live with all people cured of above chronic and criminal ailments. What a wishfull thinking though.

    Reply | Report Abuse | Link to this
  5. 5. tornado_whiz in reply to hawkeye 04:02 PM 6/25/10

    Not all vaccines lead to autism.. and there aint any empirical proof that vaccines cause autism, there may be other unknown environmental or genetic factors that are to be blamed instead..

    Take a look at this article from NewScientist (Autism rises despite MMR ban in Japan):
    http://www.newscientist.com/article/dn7076-autism-rises-despite-mmr-ban-in-japan.html

    Reply | Report Abuse | Link to this
  6. 6. aquraish 04:13 AM 7/5/10

    tornado_whiz,
    Just read your article. Very interesting. thanks for posting

    Reply | Report Abuse | Link to this
  7. 7. michele in reply to lamorpa 06:22 PM 7/11/11

    i'd like to know how you can claim that it is a "baseless, paranoid delusion" that vaccines are unsafe when the supreme court of the united states has in fact ruled that vaccines are UNAVOIDABLY UNSAFE?

    Reply | Report Abuse | Link to this
Leave this field empty

Add a Comment

You must sign in or register as a ScientificAmerican.com member to submit a comment.
Click one of the buttons below to register using an existing Social Account.

More from Scientific American

See what we're tweeting about

Scientific American Editors

More »

Free Newsletters


Get the best from Scientific American in your inbox

Solve Innovation Challenges

Powered By: Innocentive

  SA Digital
  SA Digital

Science Jobs of the Week

Email this Article

Vaccinomics: Scientists Are Devising Your Personal Vaccine

X
Scientific American Magazine

Subscribe Today

Save 66% off the cover price and get a free gift!

Learn More >>

X

Please Log In

Forgot: Password

X

Account Linking

Welcome, . Do you have an existing ScientificAmerican.com account?

Yes, please link my existing account with for quick, secure access.



Forgot Password?

No, I would like to create a new account with my profile information.

Create Account
X

Report Abuse

Are you sure?

X

Institutional Access

It has been identified that the institution you are trying to access this article from has institutional site license access to Scientific American on nature.com. To access this article in its entirety through site license access, click below.

Site license access
X

Error

X

Share this Article

X